These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32044423)

  • 41. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.
    Wintner LM; Giesinger JM; Sztankay M; Bottomley A; Holzner B;
    Trials; 2020 Oct; 21(1):849. PubMed ID: 33050917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
    Suzuki Y; Iwamoto T; Uno M; Hatono M; Kajiwara Y; Takahashi Y; Kochi M; Shien T; Kikawa Y; Uemura Y; Hagiwara Y; Yamamoto S; Taira N; Doihara H; Toyooka S
    Breast Cancer; 2023 Sep; 30(5):856-868. PubMed ID: 37422608
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation.
    Kirsch M; Mitchell SA; Dobbels F; Stussi G; Basch E; Halter JP; De Geest S
    Eur J Oncol Nurs; 2015 Feb; 19(1):66-74. PubMed ID: 25190633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
    Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validation of the caregiver Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure.
    Reeve BB; McFatrich M; Lin L; Lucas NR; Mack JW; Jacobs SS; Withycombe JS; Baker JN; Freyer DR; Hinds PS
    Cancer; 2021 May; 127(9):1483-1494. PubMed ID: 33332590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multicenter Prospective Cohort Study of the Patient-Reported Outcome Measures PRO-CTCAE and CAT EORTC QLQ-C30 in Major Abdominal Cancer Surgery (PATRONUS): A Student-Initiated German Medical Audit (SIGMA) Study.
    ; Mihaljevic AL
    Ann Surg Oncol; 2021 Jun; 28(6):3075-3089. PubMed ID: 33683524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Miyaji T; Iioka Y; Kuroda Y; Yamamoto D; Iwase S; Goto Y; Tsuboi M; Odagiri H; Tsubota Y; Kawaguchi T; Sakata N; Basch E; Yamaguchi T
    J Patient Rep Outcomes; 2017; 1(1):8. PubMed ID: 29757296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
    Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
    JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
    Steffen McLouth LE; Lycan TW; Levine BJ; Gabbard J; Ruiz J; Farris M; Grant SC; Pajewski NM; Weaver KE; Petty WJ
    Clin Lung Cancer; 2020 May; 21(3):255-263.e4. PubMed ID: 31917067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
    Park KU
    Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.
    Speck RM; Lenderking WR; Shaw JW
    J Patient Rep Outcomes; 2017; 2():35. PubMed ID: 30175317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
    Atkinson TM; Ryan SJ; Bennett AV; Stover AM; Saracino RM; Rogak LJ; Jewell ST; Matsoukas K; Li Y; Basch E
    Support Care Cancer; 2016 Aug; 24(8):3669-76. PubMed ID: 27260018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Schroeder KM; Rizzieri T; Lion RR; Mtenga N; Gisiri M; McFatrich M; Reeve BB
    J Patient Rep Outcomes; 2023 Jun; 7(1):56. PubMed ID: 37306774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.
    Gilbert A; Piccinin C; Velikova G; Groenvold M; Kuliś D; Blazeby JM; Bottomley A
    J Clin Oncol; 2022 Nov; 40(32):3770-3780. PubMed ID: 35973158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cultural adaptation and validation of the Korean version of the EORTC QLQ-CR29 in patients with colorectal cancer.
    Ihn MH; Lee SM; Son IT; Park JT; Oh HK; Kim DW; Kang SB
    Support Care Cancer; 2015 Dec; 23(12):3493-501. PubMed ID: 25824366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
    Basch E; Dueck AC; Rogak LJ; Minasian LM; Kelly WK; O'Mara AM; Denicoff AM; Seisler D; Atherton PJ; Paskett E; Carey L; Dickler M; Heist RS; Himelstein A; Rugo HS; Sikov WM; Socinski MA; Venook AP; Weckstein DJ; Lake DE; Biggs DD; Freedman RA; Kuzma C; Kirshner JJ; Schrag D
    JAMA Oncol; 2017 Aug; 3(8):1043-1050. PubMed ID: 28208174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE
    Minasian LM; O'Mara A; Mitchell SA
    Patient Relat Outcome Meas; 2022; 13():249-258. PubMed ID: 36524232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients.
    Baeksted C; Pappot H; Nissen A; Hjollund NH; Mitchell SA; Basch E; Bidstrup PE; Dalton SO; Johansen C
    J Patient Rep Outcomes; 2017; 1(1):1. PubMed ID: 29757324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
    Basch E; Rogak LJ; Dueck AC
    Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
    Taarnhøj GA; Johansen C; Lindberg H; Basch E; Dueck A; Pappot H
    Cancer Med; 2020 May; 9(9):3078-3087. PubMed ID: 32154663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.